Tests elironrasib and daraxonrasib in advanced solid tumors with KRAS G12C mutation
Tests two drugs, alone and together, in adults with advanced KRAS G12C-mutated cancers.
Plain-language title generated from the registry record
Registry title: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Key facts
- Where
- Cologne, Esslingen am Neckar, Moers, and Nuremberg, GermanySee the 4 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors that carry a KRAS G12C mutation and were treated before. Lung, colorectal and pancreatic cancers are included.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Advanced or metastatic solid tumor with a KRAS G12C mutation, not open to treatment meant to remove all of the disease. ECOG performance status 0 or 1.
- Earlier treatment
- Solid tumors must have been treated before. For one part of the study, lung cancer must have been treated with immunotherapy, chemotherapy and KRAS G12C (OFF) inhibitors. Other solid tumors must not have had KRAS G12C (OFF) inhibitors.
- Biomarker or test result
- KRAS G12C mutation, documented by pathology.
Main reasons for not taking part
- Primary central nervous system (CNS) tumors
- Active brain metastases
- Known problem of the gut that would change how drugs are absorbed
- Major surgery within 28 days before treatment
- Minor procedures not related to the study within 7 days before treatment
Read by machine on 12 November 2026.
Where in Germany
- Universitäts Klinikum KölnCologne, GermanyContact: Revolution Medicines, Inc.Taking people
- Klinikum Esslingen GmbHEsslingen am Neckar, GermanyContact: Revolution Medicines, Inc.Taking people
- Krankenhaus Bethanien MoersMoers, GermanyContact: Revolution Medicines, Inc.Taking people
- Klinkum Nurnberg Paracelsus Medical UnviersityNuremberg, GermanyContact: Revolution Medicines, Inc.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06128551
- Record updated
- 22 September 2026
- Original description
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.Read full original descriptionShow less
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Inclusion: 18 years of age; Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy; Phase 1b Dose Escalation: solid tumors, previously treated; Phase 1b Dose Expansion and Phase 2:; NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors; ECOG performance status 0 or 1; Adequate organ function.
Exclusion: Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment; Known impairment of GI function that would alter the absorption; Primary central nervous system (CNS) tumors; Active brain metastases.